Your browser doesn't support javascript.
loading
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Nguyen, Phuong H D; Ma, Siming; Phua, Cheryl Z J; Kaya, Neslihan A; Lai, Hannah L H; Lim, Chun Jye; Lim, Jia Qi; Wasser, Martin; Lai, Liyun; Tam, Wai Leong; Lim, Tony K H; Wan, Wei Keat; Loh, Tracy; Leow, Wei Qiang; Pang, Yin Huei; Chan, Chung Yip; Lee, Ser Yee; Cheow, Peng Chung; Toh, Han Chong; Ginhoux, Florent; Iyer, Shridhar; Kow, Alfred W C; Young Dan, Yock; Chung, Alexander; Bonney, Glen K; Goh, Brian K P; Albani, Salvatore; Chow, Pierce K H; Zhai, Weiwei; Chew, Valerie.
Afiliação
  • Nguyen PHD; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
  • Ma S; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Phua CZJ; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Kaya NA; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Lai HLH; School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore.
  • Lim CJ; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Lim JQ; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
  • Wasser M; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Lai L; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
  • Tam WL; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
  • Lim TKH; Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Wan WK; School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore.
  • Loh T; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Leow WQ; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Pang YH; Department of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Chan CY; Duke-NUS Medical School, Singapore, Singapore.
  • Lee SY; Department of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Cheow PC; Duke-NUS Medical School, Singapore, Singapore.
  • Toh HC; Department of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Ginhoux F; Duke-NUS Medical School, Singapore, Singapore.
  • Iyer S; Department of Pathology, Singapore General Hospital, Singapore, Singapore.
  • Kow AWC; Duke-NUS Medical School, Singapore, Singapore.
  • Young Dan Y; Department of Pathology, National University Hospital Singapore, Singapore, Singapore.
  • Chung A; Duke-NUS Medical School, Singapore, Singapore.
  • Bonney GK; National Cancer Centre, Singapore, Singapore.
  • Goh BKP; Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore, Singapore.
  • Albani S; Duke-NUS Medical School, Singapore, Singapore.
  • Chow PKH; National Cancer Centre, Singapore, Singapore.
  • Zhai W; Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore, Singapore.
  • Chew V; Duke-NUS Medical School, Singapore, Singapore.
Nat Commun ; 12(1): 227, 2021 01 11.
Article em En | MEDLINE | ID: mdl-33431814
ABSTRACT
The clinical relevance of immune landscape intratumoural heterogeneity (immune-ITH) and its role in tumour evolution remain largely unexplored. Here, we uncover significant spatial and phenotypic immune-ITH from multiple tumour sectors and decipher its relationship with tumour evolution and disease progression in hepatocellular carcinomas (HCC). Immune-ITH is associated with tumour transcriptomic-ITH, mutational burden and distinct immune microenvironments. Tumours with low immune-ITH experience higher immunoselective pressure and escape via loss of heterozygosity in human leukocyte antigens and immunoediting. Instead, the tumours with high immune-ITH evolve to a more immunosuppressive/exhausted microenvironment. This gradient of immune pressure along with immune-ITH represents a hallmark of tumour evolution, which is closely linked to the transcriptome-immune networks contributing to disease progression and immune inactivation. Remarkably, high immune-ITH and its transcriptomic signature are predictive for worse clinical outcome in HCC patients. This in-depth investigation of ITH provides evidence on tumour-immune co-evolution along HCC progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Progressão da Doença / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Progressão da Doença / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article